Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus

被引：33

作者：

Aucken, HM

Warner, M

Ganner, M

Johnson, AP

Richardson, JF

Cookson, BD

Livermore, DM

机构：

[1] Cent Publ Hlth Lab, Lab Hosp Infect, London NW9 5HT, England

[2] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England

来源：

关键词：

D O I：

10.1093/jac/46.4.639-a

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：639 / 640

页数：2

共 6 条

[1] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K
Hanaki, H
Ino, T
Yabuta, K
Oguri, T
Tenover, FC
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) : 135 - 136
[2] First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
Ploy, MC
Grélaud, C
Martin, C
de Lumley, L
Denis, F
[J]. LANCET, 1998, 351 (9110) : 1212 - 1212
[3] Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
Tenover, FC
Lancaster, MV
Hill, BC
Steward, CD
Stocker, SA
Hancock, GA
O'Hara, CM
Clark, NC
Hiramatsu, K
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) : 1020 - 1027
[4] Tenover Fred C., 2000, Clinical Microbiology Newsletter, V22, P49, DOI 10.1016/S0196-4399(00)88583-9
[5] 1999, SCIEI WEEKLY REPORTS, V33, P153
[6] 2000, MORBICITY MORTALITY, V48, P1165